Agonistic CD40 Antibodies in Cancer Treatment is a research paper published in Cancers (2021). On theSindex it has a DataRank of 0. It has been cited 106 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH grants
Grant: R01 CA227472
NIH grants
Grant: K12CA215119
NIH grants
Grant: R01 CA216846
Yale SPORE in Skin Cancer
Grant: NCI P50 CA121974
NCATS NIH HHS
Grant: UL1 TR001863
National Institutes of Health
Grant: 2P50CA121974-06A1
The RAC1 Pathway as aTarget for Melanoma Therapy
National Institutes of Health
Grant: 1R01CA216846-01
Renalase inhibition for treatment of unresectable melanoma
Influential Citations
4
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy
Additional file 1 of CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy